Precision medicine Archives

AKT inhibitor ipatasertib shows signs of effectiveness in patient trial

News and Trends 28 Oct 2022

AKT inhibitor shows signs of effectiveness in patient trial

In a trial matching new treatments to cancer patients based on the genetic make-up of their tumors, 22% of the patients treated with the AKT inhibitor drug ipatasertib had their tumors shrink. This included patients with breast cancer and endometrial cancer as well as two rarer forms – anal and salivary gland. In the majority […]

October 28, 2022 - 3 minutesmins - By Jim Cornall

Opinion 25 Oct 2022

Precision medicine research must lose its Eurocentricity

Precision medicine research relies on genetic testing at scale, but how do we reach more diverse patient populations and collect nationally representative samples? Patrick Short, CEO and co-founder of Sano Genetics, and Natasha Ratcliffe, director of community engagement and partnerships at Couch Health, explain how Eurocentricity is holding back genetics, and what can be done. […]

October 25, 2022 - 7 minutesmins - By External Contributor

More News! 24 Oct 2022

Mass production of lutetium for targeted cancer therapeutics following collaboration

An international collaboration marking the start of commercial production of lutetium-177 was celebrated in Munich between Canada-based Bruce Power, Isogen and Isotope Technologies Munich (ITM). The announcement was celebrated along with representatives of the partnership organizations during a trade mission with Vic Fedeli, Ontario’s Minister of Economic Development, Job Creation and Trade. This milestone was […]

October 24, 2022 - 4 minutesmins - By Liza Laws

News and Trends 14 Sep 2022

New study reveals first genetic links in ME and chronic fatigue syndrome

For the first time in more than 30 years, replicable genetic findings have been reported in the study into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). UK-based PrecisionLife today (September 14) unveiled the results offering new approaches for better diagnosis and treatments of patients. The data has also been submitted for peer reviewed publication and is available […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 25 Aug 2022

Scottish researchers can tap into new £300K fund

Precision Medicine Scotland Innovation Centre (PMS-IC), the national center for accelerating the advancement and adoption of precision medicine, has launched a new fund to support Scottish researchers. The $300,000 ($355,000) fund, the first offered by PMS-IC, will support research ideas to support accurate diagnosis and/or treatment based on an individual’s unique biology. Funds of up […]

August 25, 2022 - 2 minutesmins - By Jim Cornall

sano genetics trial recruitment precision medicine

Opinion 25 Jul 2022

How to improve patient recruitment in your precision medicine research

Precision medicine research relies on genetic testing at scale, but has long suffered recruitment and retention headaches. The answer, says Patrick Short, CEO of Sano Genetics, is to start early and engage participants deeply. I witnessed first-hand the power of national scale genomics research through my PhD work analyzing genome sequence data from more than […]

July 25, 2022 - 7 minutesmins - By External Contributor

In Depth 18 Jul 2022

Deep phenotyping brings accuracy to precision medicine

Biotech companies are leveraging the wealth of omics and imaging data to study deep phenotypes for a range of clinical applications including precision medicine approaches to liver disease, neurodegenerative disorders and infertility. With dozens of omics and imaging technologies in its arsenal, the biopharma industry is generating unprecedented amounts of data compared to just a […]

July 18, 2022 - 8 minutesmins - By Sachin Rawat

multiOmics Health metabolic disorders precision medicine

Opinion 11 Jul 2022

Precision medicine: the next big leap for metabolic disorders

Chronic metabolic disorders like type 2 diabetes and cardiovascular disease are a huge burden on healthcare systems, and their treatment is often fragmented and reliant on trial-and-error approaches. Rebecca Cripps and Robert Thong at MultiOmic Health explain how precision medicine is set to change the way we think about these disorders. Metabolic disorders constitute the […]

July 11, 2022 - 6 minutesmins - By External Contributor

News and Trends 31 Mar 2022

Precision Medicine Startups Increase Focus on Data Access and Privacy

Low-cost genetic sequencing is becoming increasingly accessible and profitable for companies, but data protection and ownership remains a key issue for many individuals. Sano Genetics is one of many firms driving precision medicine by creating a more mutually beneficial relationship between patients and pharma companies. The falling costs of DNA sequencing are leading to serious […]

March 31, 2022 - 4 minutesmins - By Anita Chakraverty

In Depth 23 Jun 2021

How Blockchain Companies Are Helping Us Protect Our Genomic Data

Using genomic data and the blockchain network, it is now possible to send anonymous genetic information around the world in the blink of an eye. Meet the companies that want to help us protect and control our own genetic data. As the cost of sequencing an individual genome falls and more people have access to […]

June 23, 2021 - 7 minutesmins - By Helen Albert

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

June 8, 2021 - 5 minutesmins - By Jonathan Smith

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us